This is a repository copy of Altered Cortical Microarchitecture and Bone Metabolism in Patients with Monoclonal Gammopathy of Undetermined Significance.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/84619/

Version: Accepted Version

Article:
Farr, J.N., Zhang, W., Jacques, R.M. et al. (3 more authors) (2014) Altered Cortical Microarchitecture and Bone Metabolism in Patients with Monoclonal Gammopathy of Undetermined Significance. Blood, 123 (5). ISSN 0006-4971

10.1182/blood-2013-05-505776

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
This is the accepted version of the following article:


which has been published in the final form at

http://www.bloodjournal.org/content/123/5/647
Altered Cortical Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance

Abbreviated Title: Cortical Porosity and Bone Strength in MGUS

Joshua N. Farr,1 Wei Zhang,1 Shaji K. Kumar,1 Richard M. Jacques,2 Alvin C. Ng,1 Louise K. McCready,1 S. Vincent Rajkumar,1 and Matthew T. Drake1

1College of Medicine, Mayo Clinic, Rochester, Minnesota, USA (J.N.F, W.Z., S.K.K., A.C.N., L.K.M, S.V.R, M.T.D) and 2School of Health and Related Research, University of Sheffield, United Kingdom (R.M.J).

Key words: MGUS; Bone Microarchitecture; HRpQCT; Cortical Porosity; Micro-finite Element Analysis
Key Points
MGUS patients have significantly increased cortical bone porosity and reduced bone strength relative to matched controls.

Abstract
Patients with monoclonal gammopathy of undetermined significance (MGUS) are at increased fracture risk, and we have previously shown that MGUS patients have altered trabecular bone microarchitecture compared with controls. However, there are no data on whether the porosity of cortical bone, which may play a greater role in bone strength and the occurrence of fractures, is increased in MGUS. Thus, we studied cortical porosity and bone strength (apparent modulus) using high-resolution peripheral quantitative computed tomography (HRpQCT) imaging of the distal radius in 50 MGUS patients and 100 age-, sex-, and BMI matched controls. Compared to controls, MGUS patients had both significantly higher cortical porosity (+16.8%; \(P<0.05\)) and lower apparent modulus (~8.9%; \(P<0.05\)). In conclusion, despite their larger radial bone size, MGUS patients have significantly increased cortical bone porosity and reduced bone strength relative to controls. This increased cortical porosity may explain the increased fracture risk seen in MGUS patients.
Introduction

Population-based studies have shown that fracture risk is increased in MGUS.\textsuperscript{1,2} Previously,\textsuperscript{3} we used high-resolution peripheral quantitative computed tomography (HRpQCT) imaging of the distal radius to demonstrate that MGUS patients have significantly altered trabecular bone microarchitecture, but also greater bone size relative to matched controls. However, the impact of these skeletal alterations on bone strength, which can be assessed from HRpQCT images using micro-finite element (\(\mu\)FE) analysis,\textsuperscript{4} is unknown. Moreover, evidence suggests cortical bone porosity may be more important for bone strength and fracture risk than trabecular bone microarchitectural changes.\textsuperscript{5,6}

Recent work demonstrates that the default HRpQCT cortical bone analysis previously utilized\textsuperscript{3} performs poorly for subjects with thin or porous cortices.\textsuperscript{7} Recognizing this limitation, Burghardt and colleagues\textsuperscript{8} developed a novel image processing protocol that automatically segments and quantifies cortical bone microarchitecture from HRpQCT images. This permits detection of intracortical pore space morphologically and provides a cortical porosity index shown to increase with age in men and women,\textsuperscript{5} enhancing identification of subjects at increased fracture risk.\textsuperscript{6} Notably, this technique has not yet been applied to patients with any hematologic condition.

Therefore, we utilized novel advancements in HRpQCT image processing and \(\mu\)FE analysis to determine whether MGUS patients have altered cortical bone microarchitecture and deficits in biomechanical bone strength compared to matched controls.

Methods

Subjects. After Mayo Clinic Institutional Review Board approval, subjects were recruited as previously described\textsuperscript{3} and written informed consent was obtained. Subjects included 50 patients diagnosed with MGUS according to International Myeloma Working Group criteria\textsuperscript{9} and 100 age-, sex-, and body mass index (BMI)-matched (1:2 ratio) controls from an age-stratified random sample of Olmsted County, Minnesota, residents.\textsuperscript{10} Reflecting the local ethnic composition,\textsuperscript{11} 97\% of subjects were white.
Study protocol. All procedures were conducted at the Mayo Clinic outpatient Clinical Research Unit (Rochester, Minnesota). Anthropometric data were collected on all subjects. Bone microarchitecture and strength of the non-dominant distal radius were assessed by HRpQCT; data from 3 scans (1 MGUS/2 controls) were excluded because of motion artifact.

HRpQCT imaging. Details regarding distal radial HRpQCT measurements and the default image analysis protocol have been described previously. In the present analysis, we used the recently developed extended cortical analysis to obtain cortical volumetric bone mineral density (vBMD, mg/cm³), cortical thickness (mm), cortical pore volume (mm³), and cortical porosity (%).

μFE analysis. Linear μFE models were created directly from the HRpQCT images (μFE element analysis solver v.1.15, Scanco Medical AG, Brüttisellen, Switzerland) as previously described. Biomechanical bone strength estimates (i.e., stiffness, failure load, apparent modulus) were derived from a uniaxial compression test simulating 1% compression, such that 2% of all elements had an effective strain >7000 microstrain. This test simulates a fall from standing height on the outstretched hand, trauma classically associated with Colles’ fractures. Failure loads calculated from such μFE models correlate highly (r = 0.87) with compressive loads producing Colles’ fractures in cadaveric forearms.

Statistical analysis. Comparisons of bone parameters between MGUS patients and controls were made using an analysis of variance model adjusted for age and sex. Testing was performed at a significance level of p<0.05 (two-tailed).

Results and Discussion
Figure 1A shows representative cross-sectional distal radius HRpQCT images (slice 55 of 110) from a female MGUS patient (left) and an age-, sex-, and BMI-matched control subject (right), with the MGUS patient having both cortical thinning and deficits in cortical vBMD relative to the matched control. Further, MGUS was associated with higher cortical porosity, particularly along the medial and posterior borders of the distal radius.
Clinical characteristics and bone parameters of the MGUS and control groups (Table 1) demonstrates that the MGUS and control groups were similar in age, height, weight and BMI. MGUS patients had significantly higher cortical porosity (+16.8%; \(P<0.05\); Figure 1B), tended to have higher cortical pore volumes (+15.5%; \(P=0.087\)), and had significant deficits in cortical volumetric bone mineral density (−4.5%; \(P<0.001\)) versus controls. Further, cortical thickness was lower (−6.6%) in MGUS patients, although this difference only approached significance (\(P=0.067\)). Biomechanical bone strength parameters (failure load, stiffness, and apparent modulus) were lower in MGUS patients (by −4.0%, −4.6%, and −8.9%, respectively), although only the apparent modulus difference was statistically significant (\(P<0.05\); Figure 1C).

While MGUS patients are at increased risk for fracture\(^1\)\(^2\) and progression to multiple myeloma or a related plasma cell cancer,\(^14\) clinically, MGUS patients are followed without treatment until progression.\(^15\) In this study, we used HRpQCT and μFE analysis to show that MGUS patients have altered cortical microarchitecture and lower biomechanical bone strength versus matched controls, factors likely significant for explaining their increased fracture risk.

Although dual-energy X-ray absorptiometry (DXA) is clinically used for monitoring skeletal health, it cannot separate trabecular from cortical bone, a shortcoming which limits its ability to detect changes within these skeletal compartments. An advantage of HRpQCT is that such separation is readily performed, and as indicated by our findings, HRpQCT imaging clearly demonstrates that MGUS is associated with significantly higher cortical porosity. Despite their larger radial bone size,\(^3\) MGUS patients had significantly lower cortical vBMD and tended to have thinner cortices relative to controls. These results extend our previous findings\(^3\) demonstrating altered trabecular microarchitecture with MGUS.

Another novel aspect of our analysis is the μFE models constructed to assess bone biomechanical properties in response to a simulated axial compression test.\(^4\) Our findings that failure load and stiffness both tended to be lower in MGUS patients are consistent with the suggestion that bone strength is reduced in MGUS. Notably, these deficits did not reach statistical significance, likely because of the compensatory increase in bone size seen in
MGUS patients, an increase likely resulting from progressive periosteal (outer surface) bone apposition with concomitantly increased endocortical (inner surface) resorption, ultimately resulting in cortical thinning. Such outward cortical displacement increases resistance to bending stresses, providing a partial biomechanical adaptation to limit the overall loss of bone strength resulting from decreased cortical thickness. Consistent with this premise, MGUS patients had significantly lower radial apparent modulus (bone strength corrected for cross-sectional area) compared to controls.

The importance of cortical bone morphology in bone strength and fracture prevention is highlighted by observations that cortical bone comprises over 80% of the adult skeleton, and that after age 65, most appendicular bone loss is cortical. Further, 80% of fractures after age 65 occur at predominantly cortical skeletal sites. Thus, the cortical bone deterioration we observed in MGUS patients is of significant clinical concern, and emphasizes the need for treatments that prevent such bone loss.

A limitation of our study is that currently only cross-sectional data are available. Thus, long-term consequences of the cortical bone abnormalities we observed in the MGUS patients remain unknown, although we plan to examine this question by longitudinally following this cohort. Another potential concern is that our HRpQCT measurements were limited to the radius. Lastly, future studies are necessary to determine whether the identified skeletal abnormalities are worse in patients with multiple myeloma or related plasma cell malignancies.

In conclusion, despite their larger radial bone size, MGUS patients have compromised cortical microarchitecture (i.e., increased cortical bone porosity) and reduced bone strength relative to controls. Our findings underscore the need to further delineate the factors that regulate bone microarchitecture in MGUS, both to better identify those patients at greatest fracture risk and to develop therapies to limit MGUS-associated bone loss.
Acknowledgments

The authors would like to thank James M. Peterson for data management and Margaret Holets for performing the HRpQCT scans. This work was supported by grants from the Mayo Hematologic Malignancies Program, a Mayo Career Development Award (to M.T.D.), K08 AR059138 (to M.T.D), T32 DK007352 (J.N.F), AR027065, and UL1TR000135 (Center for Translational Science Activities).

Authorship

Contribution: J.N.F, W.Z, S.K.K., S.V.R., and M.T.D. designed the study; J.N.F., W.Z., A.C.N., L.K.M., and M.T.D. performed the research; R.M.J. contributed vital new analytic tools; J.N.F and M.T.D. performed all statistical analyses. All authors were involved in interpretation of the data. J.N.F., S.V.R., and M.T.D. wrote the manuscript. All authors read, provided comments, and approved the final version of the manuscript. J.N.F., S.V.R., and M.T.D. had full access to the data in the study and take responsibility for accuracy of the data analysis.

Conflict-of-interest disclosure: None of the authors has a conflict to disclose.

Correspondence: Matthew T. Drake, M.D., Ph.D, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905; drake.matthew@mayo.edu; Tel: 507-266-0500; Fax: 507-293-3853.
References


### Tables

**Table 1. Clinical characteristics and distal radius bone parameters (derived using the extended cortical bone analysis and μFEA of HRpQCT images) in MGUS patients and matched control subjects**

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>MGUS (n = 50)</th>
<th>Control (n = 100)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male; n (%)</td>
<td>30 (60%)</td>
<td>60 (60%)</td>
<td></td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>70.5 ± 1.4</td>
<td>70.3 ± 1.0</td>
<td>0.878</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>171 ± 1.5</td>
<td>170 ± 0.9</td>
<td>0.763</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>82.2 ± 2.3</td>
<td>83.0 ± 1.6</td>
<td>0.789</td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>28.2 ± 0.7</td>
<td>28.6 ± 0.4</td>
<td>0.622</td>
</tr>
<tr>
<td>Cortical bone parameters (derived by HRpQCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortical porosity (%)</td>
<td>2.91 ± 0.19</td>
<td>2.46 ± 0.13</td>
<td>0.048</td>
</tr>
<tr>
<td>Cortical pore volume (mm$^3$)</td>
<td>17.3 ± 1.2</td>
<td>14.8 ± 0.8</td>
<td>0.087</td>
</tr>
<tr>
<td>Cortical volumetric BMD (mg/cm$^3$)</td>
<td>907 ± 8.0</td>
<td>949 ± 5.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cortical thickness (mm)</td>
<td>0.990 ± 0.030</td>
<td>1.058 ± 0.021</td>
<td>0.067</td>
</tr>
<tr>
<td>Biomechanical bone strength (derived by μFEA)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failure load (N)</td>
<td>4049 ± 112</td>
<td>4215 ± 79</td>
<td>0.230</td>
</tr>
<tr>
<td>Stiffness (kN/mm)</td>
<td>80 ± 2.3</td>
<td>84 ± 1.6</td>
<td>0.189</td>
</tr>
<tr>
<td>Apparent modulus (MPa)</td>
<td>1768 ± 67</td>
<td>1933 ± 47</td>
<td>0.045</td>
</tr>
</tbody>
</table>

Values are presented as percentage or mean ± SE and P values. Comparisons of bone parameters are adjusted for age and sex. MGUS = monoclonal gammopathy of undetermined significance; BMI = body mass index; HRpQCT = high-resolution peripheral quantitative computed tomography; BMD = bone mineral density; μFEA = micro-finite element analysis.
Figure Legend:

Figure 1. (A) Representative cross-sectional HRpQCT images of the distal radius (slice 55 of 110) in a female MGUS patient (Left Panel) and an age-, sex-, and BMI-matched control subject (Right Panel). A = anterior; P = posterior; M = medial; L = lateral. (B) Cortical Porosity and (C) Apparent Modulus (bone strength corrected for cross-sectional area) at the distal radius in MGUS patients and controls. MPa = megapascal. Data are shown as mean ± SE adjusted for age and sex. *$P<0.05$ for difference between groups.
Figure 1

A

B

C

Cortical Porosity

Apparent Modulus

%

MPa

Control

MGUS

Control

MGUS

*